New York State Added to the Monoclonal Antibody Treatment Locator
New York State locations receiving monoclonal antibody treatments were added to the Department of Health and Human Services (HHS) treatment locator on its public data hub today. Launched earlier this month with optional participation on a state-by-state basis, the treatment locator was expanded by HHS to include all sites nationally. The treatment locator is a tool that allows users to enter their location and find nearby locations where the monoclonal antibodies bamlanivimab and imdevimab/casirivimab have been shipped. In November, the US Food and Drug Administration issued emergency use authorizations for bamlanivimab and imdevimab/casirivimab. Both therapeutics are used to treat mild or moderate COVID-19 in high-risk non-hospitalized patients. Some federally qualified health centers (FQHCs) in New York began receiving allocations of monoclonal antibodies in early November.
If you are interested in learning more about this program and how to participate as an FQHC, please visit SPEED Program website.